Semaglutide Weight Management and Cardiovascular Risk Reduction

GLP-1 obesity: Key take-aways: In OASIS 1, oral semaglaglutide 50 mg showed efficacy broadly on par with injectable semaglutide 2.4 mg A high unmeet need exists within obesity-related HFpEF Semaglutide 2.4 mg demonstrated superiority on the dual primary endpoint vs placebo in the STEP HFPEF trial C O O O novo nordisk

View entire presentation